Regeneron Pharmaceuticals, Inc.

In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 6, 2026), Regeneron Pharmaceuticals, Inc. reported 2 stock positions worth $33.8 million. Its top holding was Intellia Therapeutics (NTLA) at 98.5% of the portfolio, followed by Adicet Bio (ACET, 1.5%). Compared with Q3 2025, it sold out of 2 and reduced 1. The biggest sale was an exit from Alnylam Pharmaceuticals (ALNY).

Most Recent 13F
Q2 2026
Location
TARRYTOWN, NY
CIK
0000872589
Portfolio Value
$33.8M (Q4 2025)
SEC Filing
0001104659-26-011601 ↗ filed Feb 6, 2026

Holdings Value

0$500.0M$1.0B$1.5B Q4 2024: $1.1B Q4 2024 Q1 2025: $1.2B Q1 2025 Q2 2025: $1.5B Q2 2025 Q3 2025: $700.4M Q3 2025 Q4 2025: $33.8M $33.8M Q4 2025 Q1 2026: $47.9M Q1 2026 Q2 2026: $177.2M Q2 2026

Holdings 2 stocks · $33.8M
NTLA Intellia Therapeutics Inc. 98.49% 3,702,995 $33.3M No change
ACET Adicet Bio Inc. 1.51% 60,511 $510K Reduce -93.8%

Portfolio Sells Q3 2025 → Q4 2025
ALNY Alnylam Pharmaceuticals Inc. Sold out 0.00% −90.64
ADVM Adverum Biotechnologies Inc. Sold out 0.00% −0.12
ACET Adicet Bio Inc. Reduce -93.8% 1.51% +1.40

Portfolio Buys Q3 2025 → Q4 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$177.2MPBLS, NTLA, ACET
Q1 2026 2$47.9MNTLA, ACET
Q4 2025 2$33.8MNTLA, ACET
Q3 2025 4$700.4MALNY, NTLA, ADVM, ACET
Q2 2025 4$1.5BALNY, NTLA, ACET, ADVM
Q1 2025 6$1.2BALNY, NTLA, TSVT, ADVM, ACET
Q4 2024 6$1.1BALNY, NTLA, TSVT, ACET, ADVM